Clinical Trials Browser

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1 Completed

45 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01104259 2017-08-10

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase 1 Completed

50 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01306032 2017-04-26

Phase II ABT-888 With Cyclophosphamide

Phase 2 Completed

124 enrolled 21 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01281150 2015-05-25

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

22 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Clinical Trials

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

I-SPY

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase II ABT-888 With Cyclophosphamide

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors